Associate Professor of Medicine, Vanderbilt University School of Medicine
Oncology
Dr. Igor Puzanov, MD
|
|
Give Review
Igor Puzanov is an expert in the field of Oncology. He graduated from University of Texas Southwestern Medical School. He received 13 awards: "Meaningful Use Stage 1 Certification", "Discovery Award", "Fellow", "Outstanding Contribution Award", "IMPACT Award", "Team Science Award for Cytokine Working Group", "Hematology-Oncology Outstanding Fellow Award", "Aventis Travel Award", "Amgen Travel Award", "James W. McLaughlin Fellowship Fund Travel Award", "Hoffman-La Roche Travel Award", "Dean's Award" and "Merit Scholarship". Doctor Igor Puzanov, MD is also published. He has 49 publications published. The lastest publication: "Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.' Igor Puzanov, MD is registered with Medicare and accepts Medicare payments.
Publications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
- Thyroid nodule: not as clear-cut as it seems.
- Multiple gastrointestinal polyps in patients treated with BRAF inhibitors.
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
- Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
- Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
- Treatment of NRAS-Mutant Melanoma.
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation...
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition.
- Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma.
- ?-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000).
- Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targete...
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
- Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors.
- Marked, Homogeneous, and Early 18FFluorodeoxyglucose-Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma.
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
- Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
- Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.
- A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
- Molecular targets in melanoma from angiogenesis to apoptosis.
- Opportunities and obstacles to combination targeted therapy in renal cell cancer.
- B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
- Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
- A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
- Combination targeted therapy in advanced renal cell carcinoma.
- Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
- Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
- Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
- Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
- Inhibition of mutated, activated BRAF in metastatic melanoma.
- Biological challenges of BRAF inhibitor therapy.
- Targeted molecular therapy in melanoma.
- Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
- Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Schools
CHARLES UNIVERSITY IN PRAGUE FIRST FACULTY OF MEDICINE
University Of Texas Sw Med Center
Vanderbilt University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Amerigroup (Wellpoint)
- Assurant Health
- Blue Card PPO
- Network S
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care
- Coventry Health Care of Tennessee PPO
- GEHA
- Choice Care PPO
- Medicare MCR
- PHCS Network PPO
- POMCO Group
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- WellCare
Awards
- Meaningful Use Stage 1 Certification
- Discovery Award
- Fellow
- Outstanding Contribution Award
- IMPACT Award
- Team Science Award for Cytokine Working Group
- Hematology-Oncology Outstanding Fellow Award
- Aventis Travel Award
- Amgen Travel Award
- James W. McLaughlin Fellowship Fund Travel Award
- Hoffman-La Roche Travel Award
- Dean's Award
- Merit Scholarship
Education
-
Vanderbilt University -
University of Texas Southwestern Medical School -
Charles University in Prague Faculty of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1700892502 | |
| NPPES Provider LastName | PUZANOV | |
| NPPES Provider FirstName | IGOR | |
| NPPES Provider ZIPCode | 372325100 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 777.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 69.0 | |
| Percent Opioid Claims | 8.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700892502 |
| Last Name Of The Provider | PUZANOV |
| First Name Of The Provider | IGOR |
| View All |
Similar Doctors
|
Dr. Jack W. Erter, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Madan Jagasia, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ingrid Mayer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward K. Barnes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey R. Infante, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Christina L. Derleth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine M. Lovly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carl R. Willis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamara K. Moyo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Spigel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David Head, MD
This Doctor is OpenDoctor Recommended.
|